TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
PRME

Prime Medicine, Inc.

Healthcare · Biotechnology

3.10$ +4.7% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Prime Medicine, Inc. (PRME)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 61.9% of the shares are freely tradable; institutional investors hold 66.6%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 66.6%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 23.8%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 61.9%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 25.9%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 181Mio.

Largest Shareholders

Institutions

Institutions PRME
Name Stake (%) Shares Change (%) Date
Alphabet Inc 9.13 16,562,498 +0.0 06/30/2026
BlackRock Inc 4.69 8,501,708 +2.8 03/31/2026
State Street Corp 3.50 6,345,125 +24.5 03/31/2026
ARK Investment Management LLC 3.44 6,246,827 +16.4 03/31/2026
T. Rowe Price Investment Management,Inc. 3.02 5,481,893 -22.7 03/31/2026
Vanguard Capital Management, LLC 2.47 4,474,162 +0.0 03/31/2026
Balyasny Asset Management LLC 2.27 4,123,365 +32.0 03/31/2026

Funds

Funds PRME
Name Stake (%) Shares Change (%) Date
ARK Genomic Revolution ETF 4.39 7,960,365 -0.3 08/31/2026
State Street® SPDR® S&P® Biotech ETF 3.04 5,515,489 -1.1 08/31/2026
ARK Genomic Revolution 2.66 4,830,568 +4.0 06/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?